SYnAbs and Volition ink strategic deal on epigenetic modifications targeting

SYnabs will develop monoclonal antibodies of mice, rats, and guinea pigs against 16 different post-translational modifications on histones including methylation, acetylation, phosphorylation, and mutations.

Exhibitor Data Sheet

.fairmate_js_notification_overlay { z-index: 9000; position: fixed; top: 0; bottom: 0; left: 0; right: 0; background-color: rgb(204, 204, 204); background-color: rgba(204, 204, 204, 0.7); } .fairmate_js_notification_popup_dlg { background-color: #fff !important; margin-left: auto; margin-right: auto; width: 570px; margin-top: 10%; } .fairmate_js_notification_popup_header { display: flex; justify-content: center; padding: 10px; } .fairmate_js_notification_popup_content { padding: 10px 60px 30px; } .fairmate_js_notification_popup_footer { display: flex; justify-content: center; padding-bottom: 30px; }

This page requires JavaScript

To use the full function of this web site, JavaScript needs to be enabled in your browser.

This is how you enable JavaScript in your browser settings:
Read instruction